Currently, Aragen promoters Gunupati Aparna Reddy and Davinder Singh Brar, former Ranbaxy CEO, own 33.7% each while Goldman Sachs has about 31.3%. The rest is held by an employee welfare trust and others.
This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe, it said.
ET first reported in September that Quadria is keen to acquire about 10% stake in Aragen.
The promoters and investors in Goldman Sachs-backed Aragen Life Sciences (formerly GVK Bio), plan to dilute about 10% stake at a valuation of ?10,000-12,000 crore (up to $1.5 billion) in a pre-IPO round, ET had reported.With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen. “We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO, Aragen Life Sciences.
Dr. Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, “The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization.’
Aragen posted total income of ?1,675 crore in FY24, with Ebitda at ?450 crore. Profit after tax (PAT) was ?160 crore. FY25 revenue is estimated at ?1,800 crore and PAT at ?220 crore, said sources.
Aragen has over 450 clients, including seven of the top 10 global pharmaceutical companies. With more than 4,000 employees, the firm has facilities in Hyderabad, Bengaluru, Pune and Visakhapatnam besides Morgan Hill, California.
